|
1
|
Schadendorf D, Fisher DE, Garbe C,
Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA,
McArthur G, Ribas A, et al: Melanoma. Nat Rev Disease Primers.
1:150032015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Batus M, Waheed S, Ruby C, Petersen L,
Bines SD and Kaufman HL: Optimal management of metastatic melanoma:
Current strategies and future directions. Am J Clin Dermatol.
14:179–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smalley KS, Haass NK, Brafford PA, Lioni
M, Flaherty KT and Herlyn M: Multiple signaling pathways must be
targeted to overcome drug resistance in cell lines derived from
melanoma metastases. Mol Cancer Ther. 5:1136–1144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bis S and Tsao H: Melanoma genetics: The
other side. Clin Dermatol. 31:148–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rapp UR, Goldsborough MD, Mark GE, Bonner
TI, Groffen J, Reynolds FH Jr and Stephenson JR: Structure and
biological-activity of v-raf, a unique oncogene transduced by a
retrovirus. Proc Natl Acad Sci USA. 80:4218–4222. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wellbrock C and Hurlstone A: BRAF as
therapeutic target in melanoma. Biochem Pharmacol. 80:561–567.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bucheit AD and Davies MA: Emerging
insights into resistance to BRAF inhibitors in melanoma. Biochem
Pharmacol. 87:381–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Emery CM, Vijayendran KG, Zipser MC,
Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA,
Karpova MB, et al: MEK1 mutations confer resistance to MEK and
B-RAF inhibition. Proc Natl Acad Sci USA. 106:20411–20416. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poulikakos PI, Zhang C, Bollag G, Shokat
KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK
signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hatzivassiliou G, Song K, Yen I,
Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor
SL, Vigers G, et al: RAF inhibitors prime wild-type RAF to activate
the MAPK pathway and enhance growth. Nature. 464:431–435. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heidorn SJ, Milagre C, Whittaker S, Nourry
A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer
CJ, Pritchard C and Marais R: Kinase-dead BRAF and oncogenic RAS
cooperate to drive tumor progression through CRAF. Cell.
140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Corcoran RB, Dias-Santagata D, Bergethon
K, Iafrate AJ, Settleman J and Engelman JA: BRAF gene amplification
can promote acquired resistance to MEK inhibitors in cancer cells
harboring the BRAF V600E mutation. Sci Signal. 3:ra842010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma A, Trivedi NR, Zimmerman MA,
Tuveson DA, Smith CD and Robertson GP: Mutant B-V599E-RAF regulates
growth and vascular development of malignant melanoma tumors.
Cancer Res. 65:2412–2421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sánchez-Hernández I, Baquero P, Calleros L
and Chiloeches A: Dual inhibition of (V600E)BRAF and the
PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma
cells through a MEK-independent mechanism. Cancer Lett.
314:244–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fedorenko IV, Gibney GT, Sondak VK and
Smalley KS: Beyond BRAF: Where next for melanoma therapy? Br J
Cancer. 112:217–226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li S, Li Y, Hu R, Li W, Qiu H, Cai H and
Wang S: The mTOR inhibitor AZD8055 inhibits proliferation and
glycolysis in cervical cancer cells. Oncol Lett. 5:717–721. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sondak VK, Smalley KS, Kudchadkar R,
Grippon S and Kirkpatrick P: Ipilimumab. Nat Rev Drug Discov.
10:411–412. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mullard A: 2014 FDA drug approvals. Nat
Rev Drug Discov. 14:77–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mullard A: 2013 FDA drug approvals. Nat
Rev Drug Discov. 13:85–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Flaherty KT, Yasothan U and Kirkpatrick P:
Vemurafenib. Nat Rev Drug Discov. 10:811–812. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim DH and Rossi JJ: Strategies for
silencing human disease using RNA interference. Nat Rev Genet.
8:173–184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bouchie A: Markets, venture investors and
big pharma interest in RNAi soars. Nat Biotechnol. 32:203–204.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng Y, Wang CC, Choy KW, Du Q, Chen J,
Wang Q, Li L, Chung TK and Tang T: Therapeutic potentials of gene
silencing by RNA interference: Principles, challenges, and new
strategies. Gene. 538:217–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hingorani SR, Jacobetz MA, Robertson GP,
Herlyn M and Tuveson DA: Suppression of BRAF(V599E) in human
melanoma abrogates transformation. Cancer Res. 63:5198–5202.
2003.PubMed/NCBI
|
|
28
|
Sharma A, Tran MA, Liang S, Sharma AK,
Amin S, Smith CD, Dong C and Robertson GP: Targeting
mitogen-activated protein kinase/extracellular signal-regulated
kinase kinase in the mutant (V600E) B-Raf signaling cascade
effectively inhibits melanoma lung metastases. Cancer Res.
66:8200–8209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Posch C, Moslehi H, Feeney L, Green GA,
Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T,
et al: Combined targeting of MEK and PI3K/mTOR effector pathways is
necessary to effectively inhibit NRAS mutant melanoma in vitro and
in vivo. Proc Natl Acad Sci USA. 110:4015–4020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chresta CM, Davies BR, Hickson I, Harding
T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini
P, et al: AZD8055 is a potent, selective, and orally bioavailable
ATP-competitive mammalian target of rapamycin kinase inhibitor with
in vitro and in vivo antitumor activity. Cancer Res. 70:288–298.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stahl JM, Sharma A, Cheung M, Zimmerman M,
Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L and Robertson
GP: Deregulated Akt3 activity promotes development of malignant
melanoma. Cancer Res. 64:7002–7010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shao Y and Aplin AE: Akt3-mediated
resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer
Res. 70:6670–6681. 2010. View Article : Google Scholar : PubMed/NCBI
|
